HIGH TIDE INC (HITI.CA) Stock Fundamental Analysis
TSX-V:HITI - TSX Venture Exchange - CA42981E4013 - Common Stock - Currency: CAD
HITI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. HITI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HITI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HITI has reported negative net income.
HITI had a positive operating cash flow in the past year.
HITI had negative earnings in each of the past 5 years.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -4.17%, HITI is in line with its industry, outperforming 50.00% of the companies in the same industry.
HITI has a Return On Equity (-6.91%) which is in line with its industry peers.
HITI has a Return On Invested Capital of 4.75%. This is amongst the best in the industry. HITI outperforms 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROIC | 4.75% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HITI has a better Operating Margin (2.22%) than 67.65% of its industry peers.
HITI has a Gross Margin of 25.83%. This is in the lower half of the industry: HITI underperforms 73.53% of its industry peers.
In the last couple of years the Gross Margin of HITI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
HITI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, HITI has more shares outstanding
HITI has more shares outstanding than it did 5 years ago.
HITI has a better debt/assets ratio than last year.
2.2 Solvency
HITI has an Altman-Z score of 3.03. This indicates that HITI is financially healthy and has little risk of bankruptcy at the moment.
HITI has a Altman-Z score of 3.03. This is amongst the best in the industry. HITI outperforms 91.18% of its industry peers.
The Debt to FCF ratio of HITI is 4.52, which is a neutral value as it means it would take HITI, 4.52 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HITI (4.52) is better than 82.35% of its industry peers.
HITI has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
HITI has a Debt to Equity ratio (0.30) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 3.03 |
ROIC/WACC0.57
WACC8.37%
2.3 Liquidity
HITI has a Current Ratio of 1.57. This is a normal value and indicates that HITI is financially healthy and should not expect problems in meeting its short term obligations.
HITI's Current ratio of 1.57 is in line compared to the rest of the industry. HITI outperforms 50.00% of its industry peers.
HITI has a Quick Ratio of 1.57. This is a bad value and indicates that HITI is not financially healthy enough and could expect problems in meeting its short term obligations.
HITI has a Quick ratio (0.97) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 |
3. Growth
3.1 Past
The earnings per share for HITI have decreased strongly by -1967.71% in the last year.
HITI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.22%.
HITI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 75.59% yearly.
EPS 1Y (TTM)-1967.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1258%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%5.94%
3.2 Future
The Earnings Per Share is expected to grow by 74.44% on average over the next years. This is a very strong growth
Based on estimates for the next years, HITI will show a quite strong growth in Revenue. The Revenue will grow by 11.28% on average per year.
EPS Next Y11.83%
EPS Next 2Y68.97%
EPS Next 3Y65.89%
EPS Next 5Y74.44%
Revenue Next Year11.99%
Revenue Next 2Y11.69%
Revenue Next 3Y13.18%
Revenue Next 5Y11.28%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 56.81, HITI can be considered very expensive at the moment.
73.53% of the companies in the same industry are more expensive than HITI, based on the Price/Forward Earnings ratio.
HITI is valuated expensively when we compare the Price/Forward Earnings ratio to 21.03, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 56.81 |
4.2 Price Multiples
HITI's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. HITI is cheaper than 79.41% of the companies in the same industry.
HITI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. HITI is cheaper than 73.53% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.68 | ||
| EV/EBITDA | 7.9 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HITI does not grow enough to justify the current Price/Earnings ratio.
HITI's earnings are expected to grow with 65.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y68.97%
EPS Next 3Y65.89%
5. Dividend
5.1 Amount
HITI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:HITI (6/20/2025, 7:00:00 PM)
3.06
+0.07 (+2.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners7.98%
Inst Owner ChangeN/A
Ins Owners8.81%
Ins Owner ChangeN/A
Market Cap247.98M
Analysts80
Price Target7.14 (133.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.69%
Min EPS beat(2)-11.37%
Max EPS beat(2)-10%
EPS beat(4)1
Avg EPS beat(4)-49.38%
Min EPS beat(4)-315.76%
Max EPS beat(4)139.6%
EPS beat(8)5
Avg EPS beat(8)27.31%
EPS beat(12)9
Avg EPS beat(12)32.53%
EPS beat(16)11
Avg EPS beat(16)20.21%
Revenue beat(2)1
Avg Revenue beat(2)-2.15%
Min Revenue beat(2)-5.89%
Max Revenue beat(2)1.6%
Revenue beat(4)3
Avg Revenue beat(4)-0.31%
Min Revenue beat(4)-5.89%
Max Revenue beat(4)1.9%
Revenue beat(8)5
Avg Revenue beat(8)-0.17%
Revenue beat(12)9
Avg Revenue beat(12)1.52%
Revenue beat(16)13
Avg Revenue beat(16)7.27%
PT rev (1m)2.44%
PT rev (3m)2.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-55.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-166%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 56.81 | ||
| P/S | 0.45 | ||
| P/FCF | 17.68 | ||
| P/OCF | 10 | ||
| P/B | 1.77 | ||
| P/tB | 5.01 | ||
| EV/EBITDA | 7.9 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.05
Fwd EY1.76%
FCF(TTM)0.17
FCFY5.66%
OCF(TTM)0.31
OCFY10%
SpS6.79
BVpS1.73
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -6.91% | ||
| ROCE | 6.6% | ||
| ROIC | 4.75% | ||
| ROICexc | 5.86% | ||
| ROICexgc | 14.81% | ||
| OM | 2.22% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% | ||
| FCFM | 2.55% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score5
Asset Turnover2.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 1.22 | ||
| Cap/Depr | 47.33% | ||
| Cap/Sales | 1.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 70.95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 0.97 | ||
| Altman-Z | 3.03 |
F-Score5
WACC8.37%
ROIC/WACC0.57
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1967.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1258%
EPS Next Y11.83%
EPS Next 2Y68.97%
EPS Next 3Y65.89%
EPS Next 5Y74.44%
Revenue 1Y (TTM)9.22%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%5.94%
Revenue Next Year11.99%
Revenue Next 2Y11.69%
Revenue Next 3Y13.18%
Revenue Next 5Y11.28%
EBIT growth 1Y37.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year316.17%
EBIT Next 3Y105.72%
EBIT Next 5Y67.3%
FCF growth 1Y182.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y110.28%
OCF growth 3YN/A
OCF growth 5YN/A